Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences...
Strategic Partnership Combines Maverick's GenAI-Powered Autonomous Agents With Infinx's Deep RCM Expertise to Accelerate Coding Accuracy CUPERTINO, CALIFORNIA / ACCESS...
Strategic Partnership Combines Maverick's GenAI-Powered Autonomous Agents With Infinx's Deep RCM Expertise to Accelerate Coding Accuracy CUPERTINO, CALIFORNIA / ACCESS...
SPARKS, MD / ACCESS Newswire / August 13, 2025 / TridentCare, the leading national provider of portable diagnostic services, has...
SPARKS, MD / ACCESS Newswire / August 13, 2025 / TridentCare, the leading national provider of portable diagnostic services, has...
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –...
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –...
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney...
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney...
DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial...
DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial...
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg...
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg...
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor...